S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
How to Know Which AI Company to Invest In… and When (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
The only accurate crypto trading system I know … (Ad)
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
How to Know Which AI Company to Invest In… and When (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
The only accurate crypto trading system I know … (Ad)
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
How to Know Which AI Company to Invest In… and When (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
The only accurate crypto trading system I know … (Ad)
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
How to Know Which AI Company to Invest In… and When (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
The only accurate crypto trading system I know … (Ad)
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
Free Trial
NASDAQ:OPHT

IVERIC bio (OPHT) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)
Free OPHT Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$1.13
▼
$1.39
52-Week Range
N/A
Volume
N/A
Average Volume
159,109 shs
Market Capitalization
$1.65 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
OPHT stock logo

About IVERIC bio Stock (NASDAQ:OPHT)

IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.

OPHT Stock News Headlines

November 5, 2023 | morningstar.com
Gossamer Bio Inc GOSS
June 30, 2023 | msn.com
Iveric Bio ticks higher as it sees sale to Astellas closing July 11
April 16, 2024 | Manward Press (Ad)
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
June 29, 2023 | msn.com
Iveric Bio falls amid concern about Astellas deal
May 6, 2023 | msn.com
Baird Downgrades IVERIC bio (ISEE)
May 6, 2023 | msn.com
Apellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric Bio
May 2, 2023 | msn.com
Iveric Bio (NASDAQ:ISEE) Sold for $5.9B
May 1, 2023 | msn.com
Astellas to Buy Eye-Drug Maker Iveric Bio for $5.9 Billion
April 16, 2024 | Manward Press (Ad)
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
May 1, 2023 | reuters.com
Astellas Pharma buys Iveric Bio for $5.9 billion
April 30, 2023 | msn.com
Astellas Pharma to Buy Iveric Bio for $5.9 Billion
April 30, 2023 | wsj.com
Astellas Pharma to Buy Iveric Bio for About $5.9B
April 30, 2023 | msn.com
Astellas Pharma agrees to buy Iveric Bio for $5.9 Billion
March 3, 2023 | markets.businessinsider.com
Robert W. Baird Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
March 1, 2023 | marketwatch.com
IVERIC Bio Shares Up 14% After Positive Trial Results, 4Q Losses
February 17, 2023 | marketwatch.com
Iveric Bio Shares Rise 16% After FDA Accepts New Drug App for Avacincaptad Pegol
February 16, 2023 | nasdaq.com
Deep Track Capital Now Owns 5.88% of IVERIC bio (ISEE)
February 16, 2023 | nasdaq.com
Rtw Investments Now Owns 0.60% of IVERIC bio (ISEE)
September 16, 2022 | seekingalpha.com
ISEE IVERIC bio, Inc.
September 7, 2022 | markets.businessinsider.com
Where IVERIC bio Stands With Analysts
August 25, 2022 | markets.businessinsider.com
Iveric Bio To Announce GATHER2 Trial Data In September
January 18, 2022 | thestreet.com
Why Ophthotech (OPHT) Stock Is Surging Today
August 9, 2021 | seekingalpha.com
IVERIC bio, Inc. 2021 Q2 - Results - Earnings Call Presentation
See More Headlines
Receive OPHT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2018
Today
4/16/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OPHT
CUSIP
N/A
CIK
1410939
Web
www.ophthotech.com
Phone
(212) 845-8200
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$63.09 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-141.53%
Return on Assets
-41.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.09
Quick Ratio
10.09

Sales & Book Value

Annual Sales
$209.98 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.00 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
41,420,000
Free Float
N/A
Market Cap
$1.65 billion
Optionable
Optionable
Beta
1.49
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Glenn P. Sblendorio
    President, Chief Executive Officer & Director
  • Keith Westby
    Chief Operating Officer & Senior Vice President
  • David F. Carroll
    Chief Financial Officer, Treasurer & SVP
  • Kourous A. Rezaei
    Chief Medical Officer & Senior Vice President
  • Abraham Scaria
    Chief Scientific Officer

Key Competitors

View All Competitors

OPHT Stock Analysis - Frequently Asked Questions

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:OPHT) released its quarterly earnings data on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.02.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include iShares Preferred and Income Securities ETF (PFF), Puma Biotechnology (PBYI), Incyte (INCY), Apollo Investment (AINV), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Bausch Health Companies (BHC).

This page (NASDAQ:OPHT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The “Perfect Storm” for Gold
Gold Safe Exchange
How to Know Which AI Company to Invest In… and When
Banyan Hill Publishing
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press